🇪🇺 Intranasal glugagon in European Union

EMA authorised Intranasal glugagon on 16 December 2019

Marketing authorisation

EMA — authorised 16 December 2019

  • Application: EMEA/H/C/003848
  • Marketing authorisation holder: Amphastar France Pharmaceuticals
  • Local brand name: Baqsimi
  • Indication: Baqsimi is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 4 years and over with diabetes mellitus.
  • Status: approved

Read official source →

Intranasal glugagon in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Metabolic approved in European Union

Frequently asked questions

Is Intranasal glugagon approved in European Union?

Yes. EMA authorised it on 16 December 2019.

Who is the marketing authorisation holder for Intranasal glugagon in European Union?

Amphastar France Pharmaceuticals holds the EU marketing authorisation.